First-Line Pharmacotherapy for Androgenic Alopecia
Topical minoxidil is the first-line pharmacotherapy for androgenic alopecia in both men and women, with 5% formulations (solution or foam) recommended for men and either 2% or 5% for women. 1
Treatment Approach by Sex
For Men with Male Pattern Hair Loss (MPHL)
Start with topical minoxidil 5% (solution or foam) applied twice daily. 1, 2 The 5% concentration demonstrates superior efficacy compared to 2% formulations. 1
Add oral finasteride 1 mg daily or dutasteride 0.5 mg daily as first-line systemic therapy if topical minoxidil alone is insufficient. 2 These 5α-reductase inhibitors are FDA-approved for male pattern hair loss and have strong evidence supporting their use.
For Women with Female Pattern Hair Loss (FPHL)
Initiate topical minoxidil as monotherapy first. 1 The evidence supports:
- 5% foam once daily (equivalent efficacy to 2% solution twice daily with better tolerability) 1
- 2% solution twice daily (FDA-approved dosing) 1, 2
- 5% solution twice daily (greater efficacy than 2%, though higher hypertrichosis risk) 1
The 5% foam formulation offers practical advantages: once-daily application improves adherence, and the absence of propylene glycol reduces scalp irritation and flaking compared to solutions. 1
Formulation Selection
Choose 5% foam over 5% solution when possible due to:
- Better tolerability (no propylene glycol)
- Reduced scalp pruritus and flaking 1
- Once-daily dosing option for women
- Lower (though still present) facial hypertrichosis risk
Critical Treatment Expectations
Counsel patients that minoxidil requires at least 12 months for optimal results. 1 During weeks 2-8, expect transient increased shedding as telogen hairs are shed to make way for new anagen growth—this is a normal response, not treatment failure. 1
Common adverse effects to anticipate:
- Facial hypertrichosis (more common with 5% than 2%, more with solution than foam) 1
- Scalp pruritus and flaking (primarily with propylene glycol-containing solutions) 1
- Initial shedding phase 1
When to Add Systemic Therapy in Women
Consider adding antiandrogens or 5α-reductase inhibitors when:
- Severe hair loss is present
- Clinical or biochemical hyperandrogenism exists
- Topical minoxidil alone provides inadequate response 1
For postmenopausal women with inadequate response to minoxidil:
- Finasteride 2.5-5 mg daily (NOT the 1 mg dose used in men—this is ineffective in women) 1
- Spironolactone 100-200 mg daily for at least 12 months 1
Critical contraindication: Finasteride and dutasteride are absolutely contraindicated in women of childbearing potential due to teratogenic risk (feminization of male fetus). 1 If used in premenopausal women, mandate strict contraception during treatment and for 30 days (finasteride) or 6 months (dutasteride) after discontinuation. 1
Evidence Quality Considerations
The 2019 Androgen Excess and PCOS Committee guidelines explicitly state that topical minoxidil is the only treatment with sufficient high-quality evidence from a Cochrane review, though even this evidence showed small effect sizes. 1 Most studies of other therapies in women suffer from design bias, small sample sizes, and lack of blinding. 1
For finasteride in women, the evidence is particularly problematic: 1 mg daily (the male dose) shows no benefit over placebo in postmenopausal women, while higher doses (2.5-5 mg) show improvement primarily in postmenopausal, normoandrogenic patients. 1 The data in premenopausal women remains limited and conflicting. 1
Emerging Low-Dose Oral Minoxidil
Recent 2025 consensus statements address low-dose oral minoxidil (LDOM) as an emerging option, though it remains off-label and is not yet established as first-line therapy. 3, 4 The traditional first-line approach remains topical minoxidil due to its FDA approval, established safety profile, and negligible systemic absorption. 3
Common Pitfalls to Avoid
- Do not prescribe finasteride 1 mg to women—this dose is ineffective; use 2.5-5 mg if indicated 1
- Do not use finasteride or dutasteride in women of childbearing age without absolute contraception 1
- Do not discontinue minoxidil prematurely during the initial shedding phase—educate patients this is expected 1
- Do not expect results before 12 months of consistent use 1
- Do not use flutamide despite its efficacy—hepatotoxicity risk outweighs benefits 1